Immunai

Immunology based personalized disease treatments

Analytics, Data, Drug Development
Artificial Intelligence Deep Learning Machine Learning

Business Overview

Decoding the immune system to improve health.

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.

Cutting-edge biology coupled with machine-learning to unravel the immune system. We are curating the largest proprietary data-set of multi-omic, immune-centric analyses of peripheral tissues. Our advanced analytics and data-visualization interface allows researchers to comprehensively view and interrogate data, and derive novel conclusions on the underlying mechanisms of disease. With a comprehensive view of the immune system, clinicians are better equipped to personalize and optimize treatment choices for each patient, and maximize positive outcomes. Immunai’s mission is to transform immunology by pioneering single-cell technologies coupled with the most cutting-edge AI methods.

Operating Status
Active
Founded
January 2019
Employees
70
Business model
B2B
Offering type
Software
Funding stage
Series A
Business stage
Product Development
Total funding
$80 Million
Sectors
Analytics, Data, Drug Development, Healthcare, Immunology, Personalized Treatment

Founders

Immunai
Luis Voloch
CTO
AI Expert
Immunai
Noam Solomon
CEO
AI Expert
Immunai
Danny Wells
Scientific Founder
Immunai
Ansuman Satpathy
Scientific Founder
Immunai
Dan Littman
Scientific Founder

Board Members and Advisors

Immunai
Dan Littman
Advisor
Immunai
Jimmie Ye
Advisor
Immunai
Matthew Hellmann
Advisor
Immunai
Michael Kalos
Advisor
Immunai
Rahul Satija
Advisor
Immunai
Regina Barzilay
Advisor
Immunai
Kimary Kulig
Advisor
Immunai
Larry Marton
Advisor
Immunai
Laurence Nore
Advisor
Immunai
Michael Aberman
Advisor
Immunai
Steven Averbuch
Advisor

Funding Rounds

New wpDataTable

Date Announced

Funding Round

Amount Raised

Investors

Exit Events and Acquisitions

Date Announced

Transaction

Consideration

Target

Acquirer

March 2021
Acquisition
Dropprint Genomics
Immunai

AI Technology Stack

AI employees
10
AI application
Vertical AI
AI types
Artificial Intelligence, Deep Learning, Machine Learning
ML types
Supervised Learning, Unsupervised Learning
AI tools
Docker, Keras, Pytorch, Scikit-Learn, TensorFlow
Coding
Python, R
Cloud provider
Amazon Web Services, Google Cloud AI

Research

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

Vα24-invariant natural killer T (NKT) cells have shown potent anti-tumor properties in murine tumor models and have been linked to favorable outcomes in patients with cancer. However, low numbers of these cells in humans have hindered their clinical applications. Here we report interim results from all three patients enrolled on...
The interactions between antibodies, SARS-CoV-2 and immune cells contribute to the pathogenesis of COVID-19 and protective immunity. To understand the differences between antibody responses in mild versus severe cases of COVID-19, we analyzed the B cell responses in patients 1.5 months post SARS-CoV-2 infection. Severe and not mild infection correlated...
Immunotherapies that block inhibitory checkpoint receptors on T cells have transformed the clinical care of patients with cancer1. However, whether the T cell response to checkpoint blockade relies on reinvigoration of pre-existing tumor-infiltrating lymphocytes or on recruitment of novel T cells remains unclear2,3,4. Here we performed paired single-cell RNA and...

Similar Startups

STATUS
Active
FUNDING
$6.1 M
FUNDING STAGE
Series A
STATUS
Active
FUNDING STAGE
Seed
STATUS
Active
FUNDING
$5 M
FUNDING STAGE
Seed
STATUS
Active
FUNDING
$46 M
FUNDING STAGE
Series B+
STATUS
Active
STATUS
Active
FUNDING
$29 M
FUNDING STAGE
Series B
STATUS
Active
STATUS
Active
FUNDING STAGE
Seed
STATUS
Active
FUNDING
$1.2 M
STATUS
Acquired
FUNDING
$3.3 M
FUNDING STAGE
Series A
STATUS
Acquired
FUNDING
$2.5 M
FUNDING STAGE
Series A
STATUS
Active

CONTACT

New York City
United States
180 Varick St, 6th Fl, 10014
Tel Aviv
Israel

INVESTMENT THESIS

Sign up for free

  • Save profiles to your list
  • View all funding rounds
  • Advanced sorting filter access
  • Search investment rounds
  • Search exit events